Abstract:Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive decline in multiple cognitive domains and it becomes the most common cause of dementia in the elderly. There is an urgent need for the early diagnosis and treatment of AD to ease caregiver burden and medical costs, as well as improve patients' living activities associated with the dramatic increasing number of affected individuals. Molecular imaging with target-specific probes is contributing to identify the underlying biology in AD, which benefits to the early diagnosis of AD and the evaluation of anti-AD therapy. Molecular imaging probes, such as C-11-PIB, C-11-MP4A, F-18-AV-45, and F-18-FDG, can selectively bind to special bimolecular of AD or accurately accumulate at the location of damage areas, thus become an edge tool for a better management of the diseases in the clinical practice and new drug development. In the past decades, a large variety of probes is being developed and tested to be useful for the early and accurate diagnosis of Alzheimer's disease, patient selection for disease-modifying therapeutic trials and monitoring the effect of anti-amyloid therapy. Since imaging probes may also help to guide physicians to identify those patients that could best benefit from a given therapeutic regimen, dose, or duration of drug, this paper is to present a perspective of the available imaging probes for AD, classified on different modalities. Meanwhile, recent advances of those probes that have been selected for clinical trials and are at the different stages of the US Food and Drugs Administration (FDA) approval are outlined. Additionally, future directions and specific application of imaging strategies designed for both diagnosis and treatment for AD are discussed.

Novel Indole Derivatives as Potential Imaging Agents for Alzheimer's Disease

Novel Indanone Derivatives As Potential Imaging Probes for Β‐amyloid Plaques in the Brain

Novel PET molecular probes for early diagnosis of Alzheimer's disease

Advances of Molecular Imaging Probes for the Diagnosis of Alzheimer's Disease.

Naphthofuran Derivatives As Potential Imaging Agents for Β-Amyloid Plaques in the Brain

Novel brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer's disease and mild cognitive impairment

Molecular Imaging of Alzheimer Disease

Alzheimer's Disease: Potential Pathogenesis and Imaging Findings

6-Methoxy-indanone Derivatives As Potential Probes for Β-Amyloid Plaques in Alzheimer's Disease

Development of Near-Infrared Fluorescent Probes for Use in Alzheimer’s Disease Diagnosis

Early Detection of Amyloid Pathology in Alzheimer's Disease by Molecular MRI

Development of Near-Infrared Fluorescent Probes for Use in Alzheimers Disease Diagnosis

Novel Imaging Agents for Β-Amyloid Plaque Based on the N-benzoylindole Core.

Indole-3-acetic Acid, a Potential Therapeutic Target in Alzheimer's Disease.

Current strategies for the development of fluorescence-based molecular probes for visualizing the enzymes and proteins associated with Alzheimer’s disease

Targeting Β-Amyloid Plaques and Oligomers: Development of Near-Ir Fluorescence Imaging Probes.

Molecular Imaging of Fluorinated Probes for Tau Protein and Amyloid-β Detection

Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future

Near-infrared Fluorescent Probes for Imaging of Amyloid Plaques in Alzheimer׳s Disease.

Development of A Novel Radioiodinated Compound for Amyloid and Tau Deposition Imaging in Alzheimer's Disease and Tauopathy Mouse Models

Novel Anilinophthalimide Derivatives As Potential Probes for Beta-Amyloid Plaque in the Brain